CAR-M cell therapy refers to the transfer of a specific CAR gene that has been edited into macrophages so that it has the ability to bind to the tumor cell surface by specific antigen identification and subsequently activate macrophage activity against the tumor cells. Genetically engineered CAR-M cells can not only target phagocytic tumor cells, but also change the microenvironment near the tumor by secreting pro-inflammatory cytokines, and present tumor antigens to T cells to activate the immune response of T cells to the tumor. The emergence of CAR-M opens up a new possibility for the treatment of solid tumors: to train human macrophages with specific CAR to improve phagocytosis activity and macrophage antigen presentation against tumors. Shenzhen Cell Valley will work with customers to explore the most suitable CAR structure, foreign genes and transduction conditions for macrophages to help CAR M research and development.